Reisner, Dale V.
Johnsson, Frida Dunger
Kotowsky, Nirali
Brunette, Steven
Valdecantos, Wendell
Eyerich, Kilian
Funding for this research was provided by:
Boehringer Ingelheim (The medical writing was funded by Boehringer Ingelheim)
Article History
Accepted: 24 November 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: Kilian Eyerich has received consulting fees from AbbVie, Almirall, Bristol Myers Squibb, LEO Pharma, Janssen, Lilly, Novartis, UCB, Pfizer, and Boehringer Ingelheim; grants and/or contracts from AbbVie, LEO Pharma, UCB, and Lilly; and speaking fees from AbbVie, LEO Pharma, Janssen, and Lilly. Kilian Eyerich also declares stock or stock options with Dermagnostix and Dermagnostix R&D. Nirali Kotowsky was employed by Boehringer Ingelheim at the time the study was conducted. Wendell Valdecantos and Steven Brunette are full-time employees of Boehringer Ingelheim.
: This survey received a formal Exemption from a central Institutional Review Board (IRB) on June 8, 2020, and was provided by the IRB of Advarra<sup>TM</sup> (formerly IntegReview).
: The participants of this research study voluntarily agreed to participate.
: The participants of this research study gave their consent for the publication.
: Not applicable
: Not applicable
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of this original research article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.